Review
Medicine, General & Internal
Giuseppe Sena, Daniele Paglione, Gaetano Gallo, Marta Goglia, Mariasara Osso, Bruno Nardo
Summary: This paper presents a case of a patient with hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT) who underwent surgical resection. A systematic literature review comparing the outcomes of surgical resection with other non-surgical treatments for HCC patients with PVTT was conducted. The results showed that surgical resection can be an effective first-line treatment option.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Yu-Chao Wang, Jin-Chiao Lee, Tsung-Han Wu, Chih-Hsien Cheng, Chen-Fang Lee, Ting-Jung Wu, Hong-Shiue Chou, Kun-Ming Chan, Wei-Chen Lee
Summary: The study analyzed the outcomes of patients who had undergone liver resection for HCC with PVTT, finding that factors such as tumor size and location of PVTT influenced HCC recurrence. Overall survival was significantly better in the second era compared to the first era.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2021)
Article
Gastroenterology & Hepatology
Jaehun Yang, Jong Man Kim, Jinsoo Rhu, Gyu-Seong Choi, Choon Hyuck David Kwon, Jae-Won Joh
Summary: For resectable treatment-naive solitary HCC with Vp1-Vp3 PVTT, surgery may be a more suitable initial treatment compared to TACE-RT, as patients in the surgery group had higher survival rates and better preserved liver function.
Article
Gastroenterology & Hepatology
Aline Maehringer-Kunz, Franziska I. Meyer, Felix Hahn, Lukas Mueller, Christoph Dueber, Daniel Pinto Dos Santos, Peter R. Galle, Arndt Weinmann, Roman Kloeckner, Sebastian Schotten
Summary: In Western HCC patients, the prevalence of HVTT may be underestimated, and HVTT may commonly occur with PVTT. Although isolated HVTT is less frequent, its impact on survival is similar to that of PVTT once developed.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
(2021)
Article
Surgery
Ahmed Shehta, Ahmed Farouk, Ahmed Nabieh Elghawalby, Mohamed Elshobary, Ahmed Aboelenin, Amgad Fouad, Mahmoud Abdelwahab Ali
Summary: The study evaluated the experience of liver resection for hepatocellular carcinoma patients with macroscopic portal vein invasion and found that patients with macroscopic PVI had lower overall survival rates and higher incidence of post-operative morbidities. However, there were no significant differences in terms of recurrence rate and disease-free survival rates between the two groups.
JOURNAL OF SURGICAL RESEARCH
(2021)
Article
Oncology
Jina Kim, Jason Chia-Hsien Cheng, Taek-Keun Nam, Jin Hee Kim, Byoung Kuk Jang, Wen-Yen Huang, Hiroshi Aikata, Myungsoo Kim, Jung Hyun Kwon, Jinbo Yue, Victor Ho Fun Lee, Zhaochong Zeng, Jinsil Seong
Summary: This study compared the efficacy of liver-directed combined radiotherapy (LD combined RT) with sorafenib in hepatocellular carcinoma patients presenting portal vein tumor thrombosis. The LD combined RT group showed significantly improved overall survival and a higher conversion rate to curative surgery. Despite the multimodality of the treatment, LD combined RT had comparable toxicity rates to sorafenib.
Review
Oncology
Wei Zhang, Deliang Ouyang, Zhangkan Huang, Xu Che
Summary: This study compared the efficacy of hepatic artery infusion chemotherapy (HAIC) versus sorafenib in patients with hepatocellular carcinoma (HCC) accompanied by portal vein tumor thrombus (PVTT). The results showed that HAIC group had significantly higher rates of complete response, partial response, objective response rate, and disease control rate compared to the sorafenib group. Moreover, the overall survival and progression-free survival rates were significantly higher in the HAIC group.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Jina Kim, Hwa Kyung Byun, Tae Hyung Kim, Sun Il Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Jinsil Seong
Summary: This study investigated the efficacy of liver-directed concurrent chemoradiotherapy (LD-CCRT) compared to sorafenib in hepatocellular carcinoma patients with portal vein tumor thrombosis (PVTT). The results showed that LD-CCRT led to significantly improved survival compared to sorafenib, and patients who underwent surgical treatment after LD-CCRT had even longer overall survival.
Article
Gastroenterology & Hepatology
Yizhen Fu, Wei Peng, Weixiang Zhang, Zhenyun Yang, Zili Hu, Yanxun Pang, Dandan Hu, Jinbin Chen, Juncheng Wang, Zhongguo Zhou, Li Xu, Minshan Chen, Yaojun Zhang
Summary: In the treatment of advanced hepatocellular carcinoma (HCC), hepatic arterial infusion chemotherapy (HAIC) with fluorouracil, leucovorin, and oxaliplatin (FOLFOX), lenvatinib and programmed death receptor-1 signaling inhibitors (PD1s) have been proven effective. However, the efficacy and safety of the tri-combination therapy in treating HCC patients with portal vein tumor thrombosis (PVTT) remains unknown.
JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Oncology
Hong-Tao Hu, Jun-Peng Luo, Guang-Shao Cao, Zhen Li, Ming Jiang, Chen-Yang Guo, Hang Yuan, Quan-Jun Yao, Xiang Geng, Jung-Hoon Park, Hong-Tao Cheng, Li Jiang, Jun-Li Ma, Yan Zhao, Hai-Liang Li
Summary: The study demonstrated the significant survival improvement of HCC patients with PVTT, especially in subtype IIa, when treated with TACE-(125)iodine, with minimal adverse events.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Abdul Rehman Khan, Xuyong Wei, Xiao Xu
Summary: Portal vein involvement is a feared complication of HCC, with treatment options including a combination of drugs and other modalities depending on the individual patient. While there are various therapeutic options available, the quest for the ideal combination therapy and sequence remains unanswered.
JOURNAL OF HEPATOCELLULAR CARCINOMA
(2021)
Article
Medicine, General & Internal
Calin Burciu, Roxana Sirli, Felix Bende, Renata Fofiu, Alina Popescu, Ioan Sporea, Ana-Maria Ghiuchici, Bogdan Miutescu, Mirela Danila
Summary: This study aimed to assess the performance of contrast-enhanced ultrasound (CEUS) and biological tests in characterizing portal vein thrombosis (PVT). The results showed that CEUS had excellent sensitivity and specificity in characterizing PVT. In addition, alpha-fetoprotein (AFP) levels were found to be correlated with PVT characterization. The PVT score derived from multiple regression analysis outperformed CEUS and AFP serum levels in characterizing PVT.
Article
Oncology
Yu-Ming Huang, Tsang-En Wang, Ming-Jen Chen, Ching-Chung Lin, Ching-Wei Chang, Hung-Chi Tai, Shih-Ming Hsu, Yu-Jen Chen
Summary: The predictive model based on radiomics features, clinical features, and radiation therapy dosimetric parameters significantly improved overall survival prediction in HCC patients treated with RT for PVTT.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Yanyan Cao, Tao Sun, Xiaopeng Guo, Tao Ouyang, Xuefeng Kan, Lei Chen, Bin Liang, Mingfu Wang, Chuansheng Zheng
Summary: This study compared the efficacy and safety of sorafenib-TACE (S-TACE) and apatinib-TACE (A-TACE) for HCC patients with PVTT. The results showed no significant difference in OS, TTP, and tumor response between the two groups. Adverse events related to sorafenib or apatinib were manageable, indicating A-TACE as an effective and safe alternative for these patients apart from conventional S-TACE.
FRONTIERS IN ONCOLOGY
(2021)
Article
Gastroenterology & Hepatology
Shin Hwang, Deok-Bog Moon, Ki-Hun Kim, Chul-Soo Ahn, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Sung-Gyu Lee
Summary: This study evaluated the prognostic accuracy of the ADV score in patients with HCC and PVTT, and found that the ADV score is an integrated surrogate biomarker with high prognostic accuracy in predicting tumor recurrence and patient survival under stratification.
JOURNAL OF GASTROINTESTINAL SURGERY
(2021)
Article
Oncology
Aradhya Nigam, Jason S. Hawksworth, Emily R. Winslow
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Mignote Yilma, Neil Mehta
Summary: Liver transplantation (LT) remains the optimal treatment for hepatocellular carcinoma (HCC), but considerations must be given to organ availability and risk of recurrence. In the United States, Milan criteria have been used to maximize the benefit of LT compared to alternative treatments. Advances in local regional therapy (LRT) have allowed us to downstage patients to meet Milan criteria, and newer selection criteria incorporating biomarkers and imaging are being developed to further optimize LT for HCC patients.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Anthony Bejjani, Richard S. Finn
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Ifrah Fatima, Neehar D. Parikh, Alisa Likhitsup
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Victoria Chernyak
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Mikin Patel, Anjana Pillai
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Zachary Whitham, David Hsiehchen
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Mariana Chavez-Villa, Ismael Dominguez-Rosado
Summary: Over the past 40 years, multiple staging systems have been developed for hepatocellular carcinoma (HCC) to guide treatment and determine prognosis. However, the heterogeneity of HCC and advances in diagnostic and therapeutic tools have made staging algorithms and eligibility criteria more complex. Recent advances in neoadjuvant therapy, downstaging, and adjuvant therapy have challenged traditional paradigms but also raised new questions. Although there is no perfect or universal staging system yet, models will continue to be refined as evidence advances. Individualized decision making and multidisciplinary approaches will play key roles in the management of HCC.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
